ClinicalTrials.Veeva

Menu
B

Biogenix Molecular, LLC | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Gadoquatrane
Abiraterone
177Lu-PSMA-617
Enzalutamide
BAY3547922
Prednisone
FPI-2265
PTI-122
RYZ101
[Lu-177]-PNT2002

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 16 total trials

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Met...

Active, not recruiting
Metastasis From Malignant Tumor of Prostate
Drug: 177Lu-PSMA-I&T
Drug: Abiraterone with Prednisone or Enzalutamide

The aim for this study is to determine the safety and efficacy of 67Cu-SAR-BBN in participants with Gastrin Releasing Peptide Receptor (GRPR)-express...

Enrolling
Castration-Resistant
Prostatic Neoplasms
Drug: 64Cu-SAR-BBN
Drug: 67Cu-SAR-BBN

A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT...

Enrolling
Epithelial Ovarian Cancer
Glioblastoma Multiforme
Drug: 89Zr-DFO-girentuximab

The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.

Enrolling
Prostate Cancer
Drug: Debio 4228

Researchers are studying a new potential treatment for liver cancer or other select solid cancers.To do this, researchers have developed a protein, c...

Enrolling
Solid Tumors
Hepatocellular Carcinoma (HCC)
Drug: BAY3547922
Drug: BAY3630942

This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). The dose optimization Phase 2 part will be investigating the safe...

Enrolling
Metastatic Castration-resistant Prostate Cancer
Drug: FPI-2265

In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melano...

Enrolling
Mucosal Melanoma
Melanoma Stage IV
Drug: Nivolumab
Drug: [212Pb]VMT01

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and...

Enrolling
Gastroenteropancreatic Neuroendocrine Tumor
Pancreatic NET
Drug: Lanreotide
Drug: Sunitinib

This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

Enrolling
Neuroendocrine Carcinoma Metastatic
Small-cell Lung Cancer
Drug: [212Pb]VMT-α-NET

Trial sponsors

Bayer logo
C
P
T
C
Debiopharm logo
F
Lantheus Medical Imaging logo
Pfizer logo
R

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems